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regimens	 may	 independently	 increase	 the	 risk	 of	 bleeding,	 espe‐
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1.1 | Current evidence for antithrombotic therapy 
in non‐valvular atrial fibrillation in cancer patients
There	are	limited	data	regarding	anticoagulation	for	cancer	patients	








Vitamin	K	 antagonists	 (VKAs)	 such	 as	warfarin	 reduce	 the	 risk	 of	
stroke	by	two‐thirds	in	patients	with	NVAF	when	compared	to	pa‐
tients	 on	 aspirin	 or	 placebo.19	However,	 cancer	 patients	 receiving	
warfarin	 be	 it	 for	 NVAF	 or	 venous	 thromboembolism	 (VTE)	 have	
worse	 anticoagulation	 control	 and	 worse	 outcomes	 compared	















for	 stroke/systemic	 embolism	 prevention	 in	 patients	with	NVAF,	
although	their	approval	 for	use	varies	across	countries.	These	 in‐
clude	 the	 direct	 thrombin	 inhibitor	 dabigatran	 and	 the	 factor	 Xa	
inhibitors	 rivaroxaban,	 apixaban,	 and	 edoxaban.	 The	 advantages	
of	DOACs	 include	 predictable	 pharmacokinetics	 and	 rapid	 onset	
and	offset,	which	facilitate	the	management	of	anticoagulation	 in	
case	of	 invasive	procedure.	Several	trials	have	demonstrated	that	
DOACs	 are	 at	 least	 as	 effective	 as	warfarin	 in	 the	 prevention	of	
stroke/systemic	embolism	in	patients	with	NVAF.25‒28	A	metaanal‐








Most	 of	 these	 studies	 excluded	 cancer	 patients	 directly	 (RELY	
and	 ENGAGE	 studies)	 or	 indirectly	 (ROCKET	 AF	 and	 ARISTOLE	
studies),	by	excluding	patients	with	an	expected	survival	less	than	1	
or	2	years.	Therefore,	whether	these	results	could	be	extrapolated	
to	 cancer	 patients	 is	 unknown.	 However,	 secondary	 analyses	 of	
these	studies	in	patients	with	or	without	a	history	of	cancer	or	in	pa‐
tients	who	developed	cancer	after	enrollment	have	shed	some	light	


















All	 DOACs	 are	 substrates	 for	 the	 excretory	 permeability	 gly‐
coprotein	 (P‐gp)	 system,	while	 only	 apixaban	 and	 rivaroxaban	 are	
also	mainly	metabolized	 via	 hepatic	 cytochrome	 P450	 (CYP)	 3A4.	
As	 such,	 the	use	of	DOACs	 concomitantly	with	drugs	 that	 are	 in‐
hibitors	or	inducers	of	P‐gp	or	CYP3A4	might	result	in	variability	in	
the	extent	of	 anticoagulation,	 as	well	 as	potentially	 affecting	 can‐
cer	 therapies.	 This	 potential	 drug‐drug	 interaction	was	 taken	 into	
account	 in	 the	 HOKUSAI	 cancer‐VTE	 study,	 where	 patients	 with	
cancer‐associated	 VTE	 assigned	 to	 edoxaban	 received	 a	 reduced	
dose	when	 they	 also	 received	 concomitant	 treatment	with	potent	








One	 final	 consideration	 should	 be	 the	 application	 of	 bleeding	
data	 from	 studies	 comparing	 DOACs	 with	 low‐molecular‐weight	
heparin	 (LMWH)	 for	 the	 treatment	 and	 secondary	 prophylaxis	 of	
VTE.34,35	 On	 the	 basis	 of	 major	 bleeding	 data,	 caution	 is	 advised	











ing	 non‐inferiority	 compared	with	 placebo	with	 respect	 to	 stroke	
events,	LMWH	bridging	was	associated	with	a	three‐fold	increase	in	
bleeding	compared	with	placebo.38
It	 is	 a	 matter	 of	 debate	 as	 to	 whether	 perioperative	 bridging	
data	are	 sufficient	 to	 justify	using	LMWH	to	 “bridge”	anticoagula‐
tion	during	chemotherapy.	In	these	studies,	patients	rarely	received	




Owing	 to	 the	paucity	of	data	 supporting	 the	use	of	LMWH	to	
prevent	embolic	stroke	in	NVAF,	its	long‐term	use	for	other	condi‐
tions	has	also	been	reviewed.	Data	from	the	use	of	LMWH	for	treat‐
ment	 of	 cancer‐associated	 VTE	 give	 some	 indication	 of	 bleeding	
risks,	 assuming	 similar	 doses	 are	 used	 for	 stroke	 prophylaxis.	 The	





1.2 | Clinical decision making and patient 
preferences
The	heterogeneity	of	cancer	extends	beyond	the	disease	and	 its	
stage	 and	 treatment.	 When	 making	 decisions	 about	 treatment	
regimens	 that	have	competing	attributes	 (in	 this	case	 the	 risk	of	
stroke	and	risk	of	bleeding)	clinicians	have	a	responsibility	to	con‐




focused	 on	 the	 treatment	 and	 secondary	 prophylaxis	 of	 VTE.	
These	have	suggested	LMWH	to	be	acceptable	within	the	context	
of	 the	cancer	course,	 in	part,	because	patients	place	most	value	
on	 anticoagulants	 that	 interfere	 least	 with	 their	 cancer	 treat‐
ment.40‒42	However,	while	 anticoagulation	 for	VTE	may	 be	 time	
limited,	 for	 NVAF	 it	 is	 usually	 indefinite.	 Arguably	 convenience	








In	 keeping	with	 the	mantra	 “Primum	non	 nocere,”	 it	would	 be	
remiss	not	to	consider	whether	there	are	situations	when	the	pos‐
sible	benefit	 from	chemotherapy	may	be	 less	 than	 the	harm	 from	
more	serious	complications	associated	with	NVAF,	its	comorbidities,	
and	 complicating	 stable	 anticoagulation.	The	use	of	 adjuvant	 che‐
motherapy	is	standard	in	many	cancer	regimens	because	of	estab‐





with	 high	 CHA2DS2‐VASC,	 HAS‐BLED	 scores,	 the	 increased	 risk	
of	bleeding,	stroke,	and	drug‐drug	interactions	may	pose	a	greater	
















favor	one	over	 another.	 Table	1	offers	 a	 comparative	 summary	of	
characteristics,	which	may	be	considered	when	choosing	one	agent	
over	 another.	 For	 example,	 trial	 and	 observational	 data	 suggest	
that	apixaban	may	be	safer	with	respect	 to	gastrointestinal	bleed‐
ing	risk,	while	rivaroxaban	and	edoxaban	have	the	strongest	phase	
4	 published	 data.	 Furthermore,	while	 all	 DOACS	 have	 interaction	
potential	 with	 P‐gp,	 edoxaban	 arguably	 has	 the	 most	 robust	 evi‐
dence	base	with	respect	to	dose	reduction	in	the	presence	of	P‐gp	
drugs,	since	this	was	prespecified	in	ENGAGE‐AF	and	HOKUSAI	and	
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1.	 We	 recommend	 individualized	 anticoagulation	 regimens	 after	
shared	 decision	making	with	 patients,	 based	wherever	 possible	
on	 risk	 of	 stroke,	 bleeding,	 and	 patient	 values.
2.	 In	cancer	patients	with	NVAF	already	on	an	anticoagulant	 regi‐








b	 In	 cancer	 patients	 on	 chemotherapies	 unable	 to	 tolerate	 an	






cers	with	 an	 intact	 primary	or	 patients	with	 active	 gastrointes‐
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Strength of RCT 
data for CAT
Strength of real 
world data for 
cancer and NVAF
Bleeding risk in 
cancer/NVAF
Apixaban b.d. 27% 73% + + + + +
Dabigatran b.d. 80% 20% − + + + ++
Edoxaban o.d. 50% 50% − + +++ ++ ++
Rivaroxaban o.d. 35% 65% + + ++ ++ ++
Abbreviations:	CAT,	cancer‐associated	thrombosis;	CYP3A4,	Cytochrome	P450	3A4;	DOACs,	direct	oral	anticoagulants;	NVAF,	non‐valvular	atrial	
fibrillation;	P‐gp,	P	glycoprotein;	RCT,	randomized	control	trial.
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